India’s Pharmaceutical Exports to the UK Expected to Surpass $981 Million by FY26-27, Boosted by FTA, Says Pharmexcil.
The India-UK Free Trade Agreement (FTA) has been a significant development in enhancing bilateral pharmaceutical trade. According to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), this agreement is anticipated to pave the way for zero tariffs on nearly all pharmaceutical products, strengthening market access for Indian exporters. The council projects that India’s pharmaceutical exports to the UK will grow by 8.66% to reach approximately $981.16 million by the financial year 2026-27, building on the exports of $902.96 million projected for FY2025-26. In the initial months of FY2026-27, exports demonstrated a year-on-year increase of 4.15%, indicating a positive trend in the sector.
For the common citizen, this FTA is a boon as it is expected to improve access to affordable medications stemming from enhanced competitiveness in Indian generic medicines. As India remains the largest supplier of pharmaceuticals in Europe and the third largest globally, this agreement positions the UK beneficially by reinforcing its supply chains and enabling wider collaboration between Indian and UK pharmaceutical companies. The shift to zero tariffs should not only benefit consumers by lowering drug prices but also open avenues for greater foreign direct investment (FDI) in India’s pharmaceutical sector.
Looking ahead, the Indian government and the Reserve Bank of India (RBI) will likely focus on strengthening regulatory cooperation and further refining trade frameworks to encourage robust growth in pharmaceuticals. Continuous collaboration with stakeholders in the UK, along with targeted investments in research and innovation, will be critical for both nations. As this FTA fosters a more predictable trade environment, India is expected to solidify its status as a global leader in pharmaceutical manufacturing, thus enhancing its trade surplus and sustaining long-term market growth.
Source: The Hindu
(Expert Note: This report was independently prepared by the Wealthova Economy team.)